A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

Old World Cutaneous Leishmaniasis Clinical Trial

Official title:

Topical Treatment of Old World Cutaneous Leishmaniasis With WR279396 (Paromomycin/Gentamicin Ointment): Efficacy and Tolerance of a Regimen Using an Occlusive Polyurethane Dressing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01536795
• Other study ID #: A-9768.2
• Secondary ID: IND50,098
• Status: Completed
• Phase: Phase 2
• Start date: October 2005
• Est. completion date: February 2007

Study information

• Verified date: February 2021
• Source: U.S. Army Medical Research and Development Command
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing) is more effective than WR279396 without occlusion for once daily treatment.

Extensive objective and subjective local tolerance data will also be captured during this trial, as well as surrogate markers (parasite loads and aminoglycosides concentration in the deep dermis) that may help to determine the optimal number and duration of treatments.

The results from this study will help determine the most practical treatment schedule and will answer questions that are crucial to improve the present treatment regimen with WR279396 which is twice a day for 20 days.

Description:

Forty-eight patients (48) with Old World cutaneous leishmaniasis will be randomly allocated to WR279396 treatment once a day for 20 days with an optimized polyurethane dressing (occlusion) (24 patients), or without occlusion (24 patients). All patients will be rescued with the standard of care accepted in Tunisia, if the patient is not cured. The active ingredients of WR279396 are two aminoglycosides - paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC).

Each subject will be followed for clinical cure for 90 days after the initiation of treatment. Cure is defined as 100% reepithelialization without relapse by 3 months.

Tolerance will be evaluated by local adverse reactions and by laboratory signs of systemic events.

In addition to the clinical evaluation of the CL lesions, the following parameters/clinical healing surrogates will be investigated:

1. parasite load will be determined in superficial and deep lesional dermis samples at D0 and D10. The mean parasite reduction ratio (parasite load at D10/parasite load at D0) in each group will be compared;

2. aminoglycoside concentrations in superficial and deep infiltrated dermis in each group will be compared.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: February 2007
• Est. primary completion date: February 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria: The study population will be selected from adults (18y) patients and children above 15y in Tunisia (Old World)

• Age: 15 - 75 years old

• Lesion character: each diameter (horizontal and vertical) of the lesion test must measure 7 mm, the lesion must be primarily ulcerative (i.e., not verrucous or nodular) and located in a biopsy friendly site of the body

• Parasitological diagnosis: have cutaneous leishmaniasis proven parasitologically in lesion selected for inclusion in study (lesion test).

• Informed consent: have given written informed consent to participate in the study:

(i.e. patient or legal representative).

Exclusion Criteria:

• Drug intolerance: history of known or suspected hypersensitivity or idiosyncratic reactions to aminoglycosides in the patient or immediate family members.

• Previous use of antileishmanial drugs (within 2 months) or present use of routinely nephrotoxic or ototoxic drugs.

• Potential for follow up: Have less than 4 months time remaining in present address and/or plans to leave the area for more than 30 days.

• Extent of disease: More than 10 lesions or lesion ³ 5 cm or a lesion less than 2 cm from eye, in the ear, or a lesion in the face, that in the opinion of the attending dermatologist could potentially cause significant disfigurement.

• Location of disease: mucosal involvement.

• Disseminated disease: clinically significant lymphadenitis with nodules that are painful and > 1 cm in size in the lymphatic drainage of the ulcer.

• Concomitant medical problems: significant medical problems of the kidney or liver as determined by history and by the following laboratory studies:

• Kidney: clinically significant abnormalities of urine analysis, serum levels of Creatinine, BUN, total proteins > upper limit of normal for the laboratory.

• Liver: AST or ALT > upper limit of normal for the laboratory.

• General: glucose, Na, K, > upper limit of normal or < lower limit of normal for the laboratory. Volunteers in whom these normal laboratory values are exceeded by less than 25% will not be automatically excluded. These volunteers will be evaluated on the basis of history, physical, as well as laboratory values.

• Scheduled or ongoing pregnancy as determined clinical and biological criteria.

• Presence of signs or symptoms of peripheral neuropathy, myasthenia gravis or neuromuscular block

Related Conditions & MeSH terms

• Leishmaniasis
• Leishmaniasis, Cutaneous
• Old World Cutaneous Leishmaniasis

Intervention

Drug:
• WR279,396 with Tegaderm Dressing
Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
• WR 279,396 with Gauze and Tape Dressing
Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days

Locations

Country	Name	City	State
Tunisia	Institut Pasteur	Tunis

Sponsors (1)

Lead Sponsor	Collaborator
U.S. Army Medical Research and Development Command

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Area of the Index Lesion's Ulceration by Study Day	Area of the index lesion's ulceration over time in mm2	Days 1, 10, 20, 50 and 90
Other	Area of the Index Lesion's Induration by Study Day	Area of the index lesion's induration over time in mm2	Days 1, 10, 20, 50 and 90
Other	Percentage Change in Induration Area From Baseline and Days 10, 20, 50 and 90	Percentage of change of index lesion in induration area from baseline and days 10, 20, 50 and 90	Days 10, 20, 50 and 90
Primary	Safety: Overview of Adverse Events	Safety of WR279,396 through the tracking of local, systemic and spontaneous adverse reactions	During 20 day treatment period
Secondary	Clinical Responses of Index Lesions (100% Re-epithelialization)	Efficacy will be evaluated in terms of the number of lesions cured at D50 (D1 is the first day of treatment) with no relapse by Day 90. Complete clinical respoonse is defined as 100% re-epithelialization of the index lesion by Day 50 or a > 50% re-epithelialization by Day 50 followed by complete re-epithelialization on or before Day 90, with no relapse ever having occurred from Day 50 through Day 90.	Day 50, 90